BioPharma « Terug naar discussie overzicht

Heeft CytoDyn het ultieme anti-HIV-middel??

1.070 Posts, Pagina: « 1 2 3 4 5 6 ... 49 50 51 52 53 54 | Laatste
MisterBlues
0
Echter nog steeds veel hoop...

Phase 2 Basket Trial for Solid Tumors should have results by December.
Phase 2 NASH Trial will have results by November
Phase 3 COVID Critical Interim results should be available by mid-December
Phase 3 Severe Full Trial Results should be available by March 2022
Phase 2 mTNBC Trial Results should be available by mid to late February of 2022

Notes:
I see Critical Trial having impact at interim with possibility of a trial halt and getting a very low p value.
I don't see a halt at interim for Severe Trial. I think we need the full 612 for statistical significance.

For some reason, I am seeing a BTD after phase 2 mTNBC results in late 1st quarter 2022.
(I could be wrong but I think the additional data will provide rock solid support for BTD which will further eclipse the data we currently have)

HIV BLA is a 2022 event especially with the transition away from Amerex.

Phase 2 Long Haulers is a 2022 event. I think prior trial was only exploratory and I still believe the next trial in Long haulers would be a phase 2B.

$5 to $7 share price by end of year.
Sub!et
0
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
Download as PDFNovember 16, 2021 4:00pm EST
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).

Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, said, “We are encouraged by Health Canada’s emergency use approval of leronlimab, which we believe could have potential benefit as a therapeutic option for treating mTNBC. We now plan to ask Health Canada to allow expanded access use for all mTNBC patients who might have no other treatment options. We are also seeking similar approvals in other countries and look forward to providing leronlimab for mTNBC patients, as well as for treatment of other solid tumor cancers, in the future. In addition, we will be filing for expanded access use for mTNBC patients in the U.S. shortly.”
MisterBlues
0
quote:

Sub!et schreef op 17 november 2021 12:26:

Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
Download as PDFNovember 16, 2021 4:00pm EST
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).

Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, said, “We are encouraged by Health Canada’s emergency use approval of leronlimab, which we believe could have potential benefit as a therapeutic option for treating mTNBC. We now plan to ask Health Canada to allow expanded access use for all mTNBC patients who might have no other treatment options. We are also seeking similar approvals in other countries and look forward to providing leronlimab for mTNBC patients, as well as for treatment of other solid tumor cancers, in the future. In addition, we will be filing for expanded access use for mTNBC patients in the U.S. shortly.”
Waar heb ik dat ook al weer eerder gehoord...? ;-)

Het is aardig maar stelt (nog) niet veel voor. Wel fijn voor de patiënt die nieuwe hoop heeft. Hopelijk veert de koers weer wat op.
Fortuno
0
Gelukkig! De autorisatie voor uitgifte van nieuwe aandelen is erdoor en dus is er geen korte termijn risico op faillissement meer.
MisterBlues
0
quote:

Lingus schreef op 31 maart 2022 12:02:

seekingalpha.com/news/3819087-cydy-st...

Ik hoop niet dat iemand hier nog in zit.
Het zou tijd worden dat dit oplichtersaandeel onder aanvoering van zakkenvuller Pourhassan aan de ketting wordt gelegd.

Ik weet zeker dat Pourhassan elk succesje uit de greep van de FDA als een majeure doorbraak viert en vervolgens weer trompetgeschal & trommelgeroffel webinars organiseert. :-)

Development-stage biotech, CytoDyn (OTCQB:CYDY) announced on Wednesday that the Food and Drug Administration (FDA) placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the U.S.

In addition, CytoDyn (CYDY) has decided to pause its COVID-19 trials in Brazil, subject to results from a previously scheduled meeting of its data safety monitoring committee. A decision on the timing of marketing application for HIV therapy is also currently under consideration, the company said.
MisterBlues
1
quote:

Lingus schreef op 31 maart 2022 15:03:

Pourhassan is al lang eruit geknikkerd.
Niets dan ellende achtergelaten, en koffers vol geld meegenomen. Je zag 'm af en toe met geveinsde onschuld en verbazing in de camera kijken hoe makkelijk deze scam kon worden gedaan.
MisterBlues
0
Wel slim om in te spelen op het 'Wappie-gevoel-dat-we-allemaal-opgelicht' worden. Appeleren op een gevoel van onbehagen dat we allemaal hebben. Nu nog steeds zullen er investeerders zijn die zeggen dat het allemaal de schuld is van Big Pharma die de FDA controleert. Niet alleen komen de oplichters van Cydy ermee weg...de opgelichte beleggers snappen niet eens dat ze zijn opgelicht! :-))
1.070 Posts, Pagina: « 1 2 3 4 5 6 ... 49 50 51 52 53 54 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

BEL 20 3.663,02 -30,89 -0,84% 05 jul
AEX 644,22 -15,39 -2,33% 05 jul
Germany40^ 12.567,30 +166,10 +1,34% 05 jul
Europe50^ 3.410,59 +50,76 +1,51% 05 jul
UK100 7.105,65 0,00 0,00% 05 jul
US30^ 30.941,88 0,00 0,00% 05 jul
Nasd100^ 11.773,47 0,00 0,00% 05 jul
België 10 jaar 1,9280 -0,0670 -3,36% 05 jul
US500^ 3.829,84 0,00 0,00% 05 jul
Japan225^ 26.250,54 0,00 0,00% 05 jul
Gold spot 1.770,40 +5,53 +0,31% 03:39
WTI 99,62 0,00 0,00% 05 jul
Brent 102,87 0,00 0,00% 05 jul
BTC/USD 20.117,42 -202,51 -1,00% 03:39
EUR/USD 1,0258 -0,0008 -0,08% 03:39
#/^ Index indications calculated real time, zie disclaimer

Aandelenadviezen van IEX.nl

  1. Premium
    ASML: recessievrees onnodig
  2. Premium
  3. Premium
    Onvervalste winstwaarschuwing FlatexDegiro
  4. Premium
  5. Premium
    Prosus is onderwaardering beu

Stijgers & Dalers

Stijgers Laatst +/- % tijd
Galapagos 54,900 +1,840 +3,47% 05 jul
VGP 151,400 +3,400 +2,30% 05 jul
Cofinimmo 104,600 +2,000 +1,95% 05 jul
Dalers Laatst +/- % tijd
KBC Groep 49,710 -3,270 -6,17% 05 jul
Solvay 74,820 -4,040 -5,12% 05 jul
Ageas 40,420 -1,960 -4,62% 05 jul

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront